





A 'Mission' to create healthier communities globally

Zydus Cadila is dedicated to life...

In all its dimensions. Our world is shaped by a passion for innovation, commitment to partners and concern for people in an effort to create healthier communities, globally.

About Us



- A vertically integrated global healthcare provider with strengths all along the pharma value chain
- Founded in 1952
- Listed as a 'Best Under a Billion' company from amongst 200 companies in Asia by Forbes
- Currently ranked 5th largest pharma company in India as per ORG
- Poised to emerge as one of the leading global players with sales in excess of \$1 bn by 2010
- Rapid growth in the regulated global generic markets (US, France and Brazil), to accelerate formulations exports growth
- Leveraging strengths through contract manufacturing
- More than 8000 employees worldwide
- Consolidated revenues of over USD 480 mn for 2006-07

Research and Development



Research center founded on January 24, 2000

750 scientists in three research areas

- ▶ **NCE Basic Research & Development (Ahmedabad)**
- ▶ **Finished Dosage Form Development (Ahmedabad)**
- ▶ **API Process Research (Ankleshwar)**

- Capabilities to conduct Drug Discovery and Development
 - from concept to IND enabling pre-clinical and clinical development.
- Focused therapeutic areas:
 - › Metabolic (Diabetes, Obesity and related disorders)
 - › Cardiovascular
 - › Inflammation and Pain
- The richest discovery pipeline among Indian drug discovery entities
 - › 15 active discovery programs, and 9 active development projects

New Molecular Entities in Development



Research

Project	Target	Indication	Drug Discovery	Lead Optimisation	Pre-clinical Development	IND	Phase I	Phase II	Phase III	NDA
ZYH1	PPAR alpha:gamma	Dyslipidemia	[Progress bar spanning from Drug Discovery to Phase II]							
ZY01	CB-1 antagonist	Obesity, Diabetes	[Progress bar spanning from Drug Discovery to Phase I]							
ZY11	Multi-modal	Pain	[Progress bar spanning from Drug Discovery to Phase II]							
ZYH2	PPAR alpha:gamma	Diabetes	[Progress bar spanning from Drug Discovery to Phase I]							
ZYH7	PPAR alpha	Dyslipidemia	[Progress bar spanning from Drug Discovery to Phase I]							
	Undisclosed	Diabetes	[Progress bar spanning from Drug Discovery to Phase I]							
	Undisclosed	Arthritis	[Progress bar spanning from Drug Discovery to Phase I]							
	Undisclosed	Dyslipidemia	[Progress bar spanning from Drug Discovery to Phase I]							
	Undisclosed	Atherosclerotic Plaque	[Progress bar spanning from Drug Discovery to Phase I]							




R & D Organization





- **Promotion of Scientific Activities**

- The Ramanbhai Foundation International Symposium is a biannual series of symposia devoted to the discussion of new trends in the pharmaceutical industry with a view to promoting scientific excellence in drug discovery and development.
- 4th International Symposium to be held on
“Advances in Cardiometabolic Research : Basic Science & Clinical Aspects”,
from **Feb 2-5, 2009**; at Ahmedabad, India
- Details of the previous events available at www.rbfsymposium.net



Break-up of Revenue (FY 2006-07)



- **Eight state-of-the-art plants**
 - Four formulation plants - one each at Moraiya in Ahmedabad, Goa, Baddi and Sikkim
 - Two API plants at Ankleshwar and Dabhasa.
 - An Agiolax plant in Goa
 - An API plant in Mumbai to manufacture key intermediates of Pantoprazole
- **Intermediates and APIs**
 - Specialty chemicals, fine chemicals
 - Advanced intermediates
 - High end bulk actives
 - Investigational bulk actives
- **Formulations**
 - Oral dosage forms (Tablets, hard and soft gel capsules)
 - Injectables (Sterile liquids and lyophilised)
 - Inhalers, transdermals, suppositories and vaccines
 - Formulation development for ANDA candidates at a dedicated Pharmaceutical Technology Centre
 - Development of specialised dosage forms

Proven strengths in Formulation Manufacturing

Key Strengths

- Development of New Drug Delivery Systems (NDDS)
- Development and scale-up of dosage form for ANDA

PTC - A unique effort...

Highlights

- Sole Indian company to develop soft gel capsules for iron supplements
- Indigenously developed complex typhoid vaccine

Highlights

- Moraiya plant is the largest single solid dosage plant in India
- Largest Indian suppository manufacturer

Key Strengths

- 4 formulation plants
- Unprecedented scalability

Size and Scale

A dedicated PTC with over 400 professionals developing a strong pipeline.

Strong Support Function

- Complete integration of regulatory affairs and quality assurance with numerous accreditations

Strengths in numerous novel dosage forms


Variety of Dosage Forms

- Asthma dosage forms our (DPI/MDI) key strength
- Vaccines - anti-rabies, typhoid
- Dedicated plant for oncology formulations
- Extensive expertise in sterile lyophilised powders
- Transdermal facility


Regulatory Approvals - Moraiya plant

- USFDA
- AFSSAPS (France)
- MHRA (U.K.) - Solid Orals
- MCC (South Africa)
- ANVISA (Brazil)
- PIC (Romania)
- BFAD (Philippines)
- NDA (Uganda)
- MoH (Latvia, Namibia, Ghana, Oman)

Zydus: Prioritized Markets




Top rankings in key therapeutic areas in India



* Segment ranking and Market Share refer to participated market Source: ORG-IMS (MAT)

- Proven brand building capabilities. 17 brands in top 300 pharmaceutical brands in India (as per IMS MAT Nov. 07)
- Ethical sales promotion practices and an excellent track record with Indian regulatory agencies
- More than 3000 medical representatives
- In-licensing arrangements- Schering AG, Boehringer Ingelheim, Viatrix etc.

Forging Win – Win Alliances



Differentiated capabilities at Zydus

- Skill sets to conceptualize NME/NDDS programme & develop “proof of concept”

- Capabilities to conduct Clinical studies with GCP compliance

- Regulatory filings made in >60 countries worldwide



- Infrastructure to conduct GLP regulatory toxicity, clinical supply manufacturing, process development & other development work for NCE/NDDS

- USFDA Approved facilities to manufacture APIs/intermediates, Finished Dosage Form & NDDS products



A vision that unleashes value

“Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over \$1 bn by 2010;

we shall achieve sales of over \$3 bn by 2015 and be a research-based pharmaceutical company by 2020.”

Thank You

This presentation contains confidential information and may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims any obligation to revise any forward-looking statements .

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Cadila Healthcare Ltd..